Nat Commun:原发性肝癌肺转移存在骤变拐点, CALML3基因可抑制肝癌生长和肺转移

2018-04-10 钟萱 复旦大学附属中山医院

近期,复旦大学附属中山医院肝肿瘤内科夏景林教授与中科院细胞生化所陈洛南研究员课题组进行合作,首次成功鉴定肝癌肺转移发生前的临界阶段,发现原发性肝癌肺转移存在骤变拐点,并首次报道了钙离子传导蛋白(calmodulin-like-protein,简称CALML3)可抑制肝癌生长和肺转移。相关研究成果以“Dynamic network biomarker indicates pulmonary meta

近期,复旦大学附属中山医院肝肿瘤内科夏景林教授与中科院细胞生化所陈洛南研究员课题组进行合作,首次成功鉴定肝癌肺转移发生前的临界阶段,发现原发性肝癌肺转移存在骤变拐点,并首次报道了钙离子传导蛋白(calmodulin-like-protein,简称CALML3)可抑制肝癌生长和肺转移。相关研究成果以“Dynamic network biomarker indicates pulmonary metastasis at the tipping point of hepatocellular carcinoma”为题发表于《自然·通讯》上。

原发性肝癌素有癌王之称,是我国乃至全球的高发恶性肿瘤之一。转移复发是影响生存率的关键因素,早发现早干预成为了攻克肝癌转移研究的难点和热点之一。肺是肝癌转移最常见的部位。肝癌肺转移的发生过程及其机制尚不明确。

课题组利用高转移人肝癌裸鼠模型,采用全基因组转录表达谱芯片,测定肝癌肺转移不同阶段的基因变化,利用原创性的动态网络生物标记物(Dynamic network biomarker,简称DNB)方法,发现肿瘤移植后第3周是肝癌肺转移发生的临界阶段,并成功鉴定具有“早期预警价值”的DNB核心基因。为了深入探讨DNB核心基因在促肝癌肺转移发生的作用机制,课题组进一步鉴定到DNB中起重要作用的CALML3,对其在肝癌肺转移中的作用及临床预后价值进行深入研究。



课题组在体内外实验中发现,CALML3是一个抑癌基因,它对肝癌生长和肺转移有明显的抑制作用。在270例肝癌手术切除患者中114例CALML3表达阳性,而这些表达阳性的患者术后生存率显着高于156例CALML3表达阴性者,而且CALML3表达阳性复发转移率也显着低于表达阴性者。



该项目研究得到了国家重点研发计划蛋白质专项,中科院先导专项及国家自然基金的资助。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2087319, encodeId=4119208e31988, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 25 15:42:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882954, encodeId=6ea81882954c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 08 02:42:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846658, encodeId=b6461846658cd, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Sep 07 00:42:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756860, encodeId=1c281e5686009, content=<a href='/topic/show?id=1311561e944' target=_blank style='color:#2F92EE;'>#拐点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56179, encryptionId=1311561e944, topicName=拐点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deb237270339, createdName=1249859em50(暂无昵称), createdTime=Tue Mar 12 21:42:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305499, encodeId=495a30549965, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:34:04 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257487, encodeId=ef10125e48729, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555521, encodeId=9c251555521ee, content=<a href='/topic/show?id=6d4f8232623' target=_blank style='color:#2F92EE;'>#肺转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82326, encryptionId=6d4f8232623, topicName=肺转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6914619384, createdName=licz0428, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-12-25 liuli5079
  2. [GetPortalCommentsPageByObjectIdResponse(id=2087319, encodeId=4119208e31988, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 25 15:42:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882954, encodeId=6ea81882954c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 08 02:42:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846658, encodeId=b6461846658cd, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Sep 07 00:42:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756860, encodeId=1c281e5686009, content=<a href='/topic/show?id=1311561e944' target=_blank style='color:#2F92EE;'>#拐点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56179, encryptionId=1311561e944, topicName=拐点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deb237270339, createdName=1249859em50(暂无昵称), createdTime=Tue Mar 12 21:42:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305499, encodeId=495a30549965, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:34:04 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257487, encodeId=ef10125e48729, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555521, encodeId=9c251555521ee, content=<a href='/topic/show?id=6d4f8232623' target=_blank style='color:#2F92EE;'>#肺转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82326, encryptionId=6d4f8232623, topicName=肺转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6914619384, createdName=licz0428, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-05-08 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=2087319, encodeId=4119208e31988, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 25 15:42:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882954, encodeId=6ea81882954c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 08 02:42:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846658, encodeId=b6461846658cd, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Sep 07 00:42:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756860, encodeId=1c281e5686009, content=<a href='/topic/show?id=1311561e944' target=_blank style='color:#2F92EE;'>#拐点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56179, encryptionId=1311561e944, topicName=拐点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deb237270339, createdName=1249859em50(暂无昵称), createdTime=Tue Mar 12 21:42:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305499, encodeId=495a30549965, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:34:04 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257487, encodeId=ef10125e48729, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555521, encodeId=9c251555521ee, content=<a href='/topic/show?id=6d4f8232623' target=_blank style='color:#2F92EE;'>#肺转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82326, encryptionId=6d4f8232623, topicName=肺转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6914619384, createdName=licz0428, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2087319, encodeId=4119208e31988, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 25 15:42:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882954, encodeId=6ea81882954c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 08 02:42:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846658, encodeId=b6461846658cd, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Sep 07 00:42:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756860, encodeId=1c281e5686009, content=<a href='/topic/show?id=1311561e944' target=_blank style='color:#2F92EE;'>#拐点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56179, encryptionId=1311561e944, topicName=拐点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deb237270339, createdName=1249859em50(暂无昵称), createdTime=Tue Mar 12 21:42:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305499, encodeId=495a30549965, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:34:04 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257487, encodeId=ef10125e48729, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555521, encodeId=9c251555521ee, content=<a href='/topic/show?id=6d4f8232623' target=_blank style='color:#2F92EE;'>#肺转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82326, encryptionId=6d4f8232623, topicName=肺转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6914619384, createdName=licz0428, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2087319, encodeId=4119208e31988, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 25 15:42:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882954, encodeId=6ea81882954c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 08 02:42:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846658, encodeId=b6461846658cd, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Sep 07 00:42:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756860, encodeId=1c281e5686009, content=<a href='/topic/show?id=1311561e944' target=_blank style='color:#2F92EE;'>#拐点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56179, encryptionId=1311561e944, topicName=拐点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deb237270339, createdName=1249859em50(暂无昵称), createdTime=Tue Mar 12 21:42:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305499, encodeId=495a30549965, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:34:04 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257487, encodeId=ef10125e48729, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555521, encodeId=9c251555521ee, content=<a href='/topic/show?id=6d4f8232623' target=_blank style='color:#2F92EE;'>#肺转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82326, encryptionId=6d4f8232623, topicName=肺转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6914619384, createdName=licz0428, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
    2018-04-13 大爰

    学习了谢谢分享!!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2087319, encodeId=4119208e31988, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 25 15:42:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882954, encodeId=6ea81882954c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 08 02:42:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846658, encodeId=b6461846658cd, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Sep 07 00:42:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756860, encodeId=1c281e5686009, content=<a href='/topic/show?id=1311561e944' target=_blank style='color:#2F92EE;'>#拐点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56179, encryptionId=1311561e944, topicName=拐点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deb237270339, createdName=1249859em50(暂无昵称), createdTime=Tue Mar 12 21:42:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305499, encodeId=495a30549965, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:34:04 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257487, encodeId=ef10125e48729, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555521, encodeId=9c251555521ee, content=<a href='/topic/show?id=6d4f8232623' target=_blank style='color:#2F92EE;'>#肺转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82326, encryptionId=6d4f8232623, topicName=肺转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6914619384, createdName=licz0428, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2087319, encodeId=4119208e31988, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Tue Dec 25 15:42:00 CST 2018, time=2018-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882954, encodeId=6ea81882954c4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Tue May 08 02:42:00 CST 2018, time=2018-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846658, encodeId=b6461846658cd, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Fri Sep 07 00:42:00 CST 2018, time=2018-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756860, encodeId=1c281e5686009, content=<a href='/topic/show?id=1311561e944' target=_blank style='color:#2F92EE;'>#拐点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56179, encryptionId=1311561e944, topicName=拐点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=deb237270339, createdName=1249859em50(暂无昵称), createdTime=Tue Mar 12 21:42:00 CST 2019, time=2019-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=305499, encodeId=495a30549965, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Fri Apr 13 22:34:04 CST 2018, time=2018-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257487, encodeId=ef10125e48729, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555521, encodeId=9c251555521ee, content=<a href='/topic/show?id=6d4f8232623' target=_blank style='color:#2F92EE;'>#肺转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82326, encryptionId=6d4f8232623, topicName=肺转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6914619384, createdName=licz0428, createdTime=Thu Apr 12 05:42:00 CST 2018, time=2018-04-12, status=1, ipAttribution=)]

相关资讯

2017年版中国肝癌诊断和治疗规范解读

2017 年原发性肝癌诊疗规范( 简称规范) 已由中国国家卫生与计划生育委员会( 国家卫计委) 公布,并建议各医院遵照实施。这个规范是在2011年中国国家卫生部组织编写的《原发性肝癌诊疗规范》基础上的更新。最重要的特征是增加了肝癌分期以方便临床使用,此外这个规范主要依据来自中国学者的经验和研究结果使之更为适合中国肝癌患者的特点,而且重视多学科联合诊治。这个规范还特别强调循证医学的证据支持,依据牛津

2016注射用洛铂在原发性肝癌TACE治疗中的专家共识发布

注射用洛铂是一种我国完全拥有自主知识产权的新型铂类抗肿瘤药物,自2004年上市以来已经积累了110 000多例肝癌患者的临床用药经验。为进一步规范、指导临床医生使用注射用洛铂,更好的为肝癌患者服务,中国医师协会介入医师分会组织全国专家,结合我国多个肝癌诊疗规范和指南制定本专家共识,以供临床实践中参考应用。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载) 

Lancet Oncol:索拉非尼不能作为原发性肝癌切除或消融后的辅助治疗的有效干预

目前肝癌患者辅助治疗的护理还没有标准。这项试验的目的是评估索拉非尼与安慰剂作为辅助治疗肝癌患者手术切除或局部消融术后的疗效性和安全性。这一阶段3,双盲,对肝癌患者安慰剂对照研究在28个国家202个地点(医院和研究中心)进行,参与者为手术切除(n=900)或局部消融(n=214)后达到完全放射反应的肝癌患者。根据使用交互式语音响应系统的块随机化方案(四个块大小),患者被随机分配(1:1)接受400m

盘点:近期原发性肝癌相关研究进展

原发性肝癌是我国常见的恶性肿瘤之一,高发于东南沿海地区。我国肝癌病人的中位年龄为40~50岁,男性比女性多见。其病因和发病机制尚未确定。【1】Lancet Oncol:索拉非尼不能作为原发性肝癌切除或消融后的辅助治疗的有效干预目前肝癌患者辅助治疗的护理还没有标准。这项试验的目的是评估索拉非尼与安慰剂作为辅助治疗肝癌患者手术切除或局部消融术后的疗效性和安全性。这是一针对肝癌患者的双盲、安慰剂对照Ⅲ期

原发性肝癌诊疗规范(2017 年版)更新解读

2017 年6 月中华人民共和国国家卫生和计划生育委员会发布了基于循证医学证据的《原发性肝癌诊疗规范(2017 年版)》。新版规范对肝细胞癌(hepatocellular carcinoma, HCC)的诊断、分期和治疗均进行了更新。本文现就更新内容进行描述和阐释。

《原发性肝癌诊疗规范(2017年版)》解读

我国是肝癌大国,全球每年一半以上的新发肝癌病例发生在中国。我国的肝癌患者有其自身的特点,多具有肝炎和肝硬化背景,这与肿瘤的治疗方式选择和预后密切相关。国家卫生和计划生育委员会在2011 年发布了我国原发性肝癌诊疗规范,倡导以外科为主的多学科联合的综合治疗。这部具有中国特色的肝癌诊疗规范的出台有非常重要的现实意义,它为全世界的肝癌诊治提供了中国经验。近些年随着对该规范不断的深入应用,国家卫生和计划生